World Health Organization. Global tuberculosis report., 2022. Available From: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022

World Health Organization. Global tuberculosis report., 2021. Available From: https://www.who.int/publications-detail-redirect/9789240037021

Gopalaswamy, R.; Shanmugam, S.; Mondal, R.; Subbian, S. Of tuberculosis and non-tuberculous mycobacterial infections – a comparative analysis of epidemiology, diagnosis and treatment. J. Biomed. Sci., 2020, 27(1), 74.
[http://dx.doi.org/10.1186/s12929-020-00667-6] [PMID: 32552732]

Centers for Disease Control and Prevention (CDC). Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb. Mortal. Wkly. Rep., 2009, 58(1), 7-10.
[PMID: 19145221]

Wu, M.L.; Aziz, D.B.; Dartois, V.; Dick, T. NTM drug discovery: Status, gaps and the way forward. Drug Discov. Today, 2018, 23(8), 1502-1519.
[http://dx.doi.org/10.1016/j.drudis.2018.04.001] [PMID: 29635026]

Lewinsohn, D.M.; Leonard, M.K.; LoBue, P.A.; Cohn, D.L.; Daley, C.L.; Desmond, E.; Keane, J.; Lewinsohn, D.A.; Loeffler, A.M.; Mazurek, G.H.; O’Brien, R.J.; Pai, M.; Richeldi, L.; Salfinger, M.; Shinnick, T.M.; Sterling, T.R.; Warshauer, D.M.; Woods, G.L. Official american thoracic society/infectious diseases society of america/centers for disease control and prevention clinical practice guidelines: Diagnosis of tuberculosis in adults and children. Clin. Infect. Dis., 2017, 64(2), 111-115.
[http://dx.doi.org/10.1093/cid/ciw778] [PMID: 28052967]

Floyd, K.; Glaziou, P.; Zumla, A.; Raviglione, M. The global tuberculosis epidemic and progress in care, prevention, and research: An overview in year 3 of the End TB era. Lancet Respir. Med., 2018, 6(4), 299-314.
[http://dx.doi.org/10.1016/S2213-2600(18)30057-2] [PMID: 29595511]

Kohanski, M.A.; Dwyer, D.J.; Collins, J.J. How antibiotics kill bacteria: From targets to networks. Nat. Rev. Microbiol., 2010, 8(6), 423-435.
[http://dx.doi.org/10.1038/nrmicro2333] [PMID: 20440275]

Cynamon, M.H.; Sklaney, M. Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis. Antimicrob. Agents Chemother., 2003, 47(8), 2442-2444.
[http://dx.doi.org/10.1128/AAC.47.8.2442-2444.2003] [PMID: 12878502]

Aldred, K.J.; Kerns, R.J.; Osheroff, N. Mechanism of quinolone action and resistance. Biochemistry, 2014, 53(10), 1565-1574.
[http://dx.doi.org/10.1021/bi5000564] [PMID: 24576155]

Hooper, D.C. Mechanisms of action of antimicrobials: Focus on fluoroquinolones. Clin. Infect. Dis., 2001, 32(Suppl. 1), S9-S15.
[http://dx.doi.org/10.1086/319370] [PMID: 11249823]

Zhang, Y.; Yew, W.W. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis., 2009, 13(11), 1320-1330.
[PMID: 19861002]

Abbadi, S.; Rashed, H.G.; Morlock, G.P.; Woodley, C.L.; El Shanawy, O.; Cooksey, R.C. Characterization of IS6110 restriction fragment length polymorphism patterns and mechanisms of antimicrobial resistance for multidrug-resistant isolates of Mycobacterium tuberculosis from a major reference hospital in Assiut, Egypt. J. Clin. Microbiol., 2001, 39(6), 2330-2334.
[http://dx.doi.org/10.1128/JCM.39.6.2330-2334.2001] [PMID: 11376084]

Arbex, M.A.; Varella, M.C.; Siqueira, H.R.; Mello, F.A. Antituberculosis drugs: Drug interactions, adverse effects, and use in special situations. Part 1: First-line drugs. J. Bras. Pneumol., 2010, 36(5), 626-640.
[http://dx.doi.org/10.1590/S1806-37132010000500016] [PMID: 21085830]

Schito, M.; Migliori, G.B.; Fletcher, H.A.; McNerney, R.; Centis, R.; D’Ambrosio, L.; Bates, M.; Kibiki, G.; Kapata, N.; Corrah, T.; Bomanji, J.; Vilaplana, C.; Johnson, D.; Mwaba, P.; Maeurer, M.; Zumla, A. Perspectives on advances in tuberculosis diagnostics, drugs, and vaccines. Clin. Infect. Dis., 2015, 61(61)(Suppl. 3), S102-S118.
[http://dx.doi.org/10.1093/cid/civ609] [PMID: 26409271]

Zimhony, O.; Vilchèze, C.; Jacobs, W.R., Jr Characterization of Mycobacterium smegmatis expressing the Mycobacterium tuberculosis fatty acid synthase I (fas1) gene. J. Bacteriol., 2004, 186(13), 4051-4055.
[http://dx.doi.org/10.1128/JB.186.13.4051-4055.2004] [PMID: 15205406]

Parvez, M.M.; Jung, J.A.; Shin, H.J.; Kim, D.H.; Shin, J.G. Characterization of 22 antituberculosis drugs for inhibitory interaction potential on organic anionic transporter polypeptide (OATP)-mediated uptake. Antimicrob. Agents Chemother., 2016, 60(5), 3096-3105.
[http://dx.doi.org/10.1128/AAC.02765-15] [PMID: 26976869]

Slayden, R.A.; Barry, C.E., III The genetics and biochemistry of isoniazid resistance in Mycobacterium tuberculosis. Microbes Infect., 2000, 2(6), 659-669.
[http://dx.doi.org/10.1016/S1286-4579(00)00359-2] [PMID: 10884617]

Pimentel, A.L.; de Lima Scodro, R.B.; Caleffi-Ferracioli, K.R.; Siqueira, V.L.D.; Campanerut-Sá, P.A.Z.; Lopes, L.D.G.; de Almeida, A.L.; Cardoso, R.F.; Seixas, F.A.V. Mutations in catalase-peroxidase KatG from isoniazid resistant Mycobacterium tuberculosis clinical isolates: Insights from molecular dynamics simulations. J. Mol. Model., 2017, 23(4), 121.
[http://dx.doi.org/10.1007/s00894-017-3290-3] [PMID: 28303436]

Tseng, S.T.; Tai, C.H.; Li, C.R.; Lin, C.F.; Shi, Z.Y. The mutations of katG and inhA genes of isoniazid-resistant Mycobacterium tuberculosis isolates in Taiwan. J. Microbiol. Immunol. Infect., 2015, 48(3), 249-255.
[http://dx.doi.org/10.1016/j.jmii.2013.08.018] [PMID: 24184004]

Takayama, K.; Kilburn, J.O. Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis. Antimicrob. Agents Chemother., 1989, 33(9), 1493-1499.
[http://dx.doi.org/10.1128/AAC.33.9.1493] [PMID: 2817850]

Halouska, S.; Fenton, R.J.; Zinniel, D.K.; Marshall, D.D.; Barletta, R.G.; Powers, R. Metabolomics analysis identifies d-Alanine-d-Alanine ligase as the primary lethal target of d-Cycloserine in mycobacteria. J. Proteome Res., 2014, 13(2), 1065-1076.
[http://dx.doi.org/10.1021/pr4010579] [PMID: 24303782]

Akbergenov, R.; Shcherbakov, D.; Matt, T.; Duscha, S.; Meyer, M.; Wilson, D.N.; Böttger, E.C. Molecular basis for the selectivity of antituberculosis compounds capreomycin and viomycin. Antimicrob. Agents Chemother., 2011, 55(10), 4712-4717.
[http://dx.doi.org/10.1128/AAC.00628-11] [PMID: 21768509]

Feng, Z.; Barletta, R.G. Roles of Mycobacterium smegmatis D-alanine:D-alanine ligase and D-alanine racemase in the mechanisms of action of and resistance to the peptidoglycan inhibitor D-cycloserine. Antimicrob. Agents Chemother., 2003, 47(1), 283-291.
[http://dx.doi.org/10.1128/AAC.47.1.283-291.2003] [PMID: 12499203]

Hwang, T.J.; Wares, D.F.; Jafarov, A.; Jakubowiak, W.; Nunn, P.; Keshavjee, S. Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: A meta-analysis [Review article]. Int. J. Tuberc. Lung Dis., 2013, 17(10), 1257-1266.
[http://dx.doi.org/10.5588/ijtld.12.0863] [PMID: 23735593]

DeBarber, A.E.; Mdluli, K.; Bosman, M.; Bekker, L.G.; Barry, C.E. III Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA, 2000, 97(17), 9677-9682.
[http://dx.doi.org/10.1073/pnas.97.17.9677] [PMID: 10944230]

Morlock, G.P.; Metchock, B.; Sikes, D.; Crawford, J.T.; Cooksey, R.C. ethA, inhA, and katG Loci of Ethionamide-Resistant Clinical Mycobacterium tuberculosis Isolates. Antimicrob. Agents Chemother., 2003, 47(12), 3799-3805.
[http://dx.doi.org/10.1128/AAC.47.12.3799-3805.2003] [PMID: 14638486]

Johnson, R.; Streicher, E.M.; Louw, G.E.; Warren, R.M.; van Helden, P.D.; Victor, T.C. Drug resistance in Mycobacterium tuberculosis. Curr. Issues Mol. Biol., 2006, 8(2), 97-111.
[PMID: 16878362]

Chien, J.Y.; Chiu, W.Y.; Chien, S.T.; Chiang, C.J.; Yu, C.J.; Hsueh, P.R. Mutations in gyrA and gyrB among Fluoroquinolone and Multidrug-Resistant Mycobacterium tuberculosis Isolates. Antimicrob. Agents Chemother., 2016, 60(4), 2090-2096.
[http://dx.doi.org/10.1128/AAC.01049-15] [PMID: 26787695]

Chen, J.; Chen, Z.; Li, Y.; Xia, W.; Chen, X.; Chen, T.; Zhou, L.; Xu, B.; Xu, S. Characterization of gyrA and gyrB mutations and fluoroquinolone resistance in Mycobacterium tuberculosis clinical isolates from Hubei Province, China. Braz. J. Infect. Dis., 2012, 16(2), 136-141.
[http://dx.doi.org/10.1590/S1413-86702012000200005] [PMID: 22552454]

Chang, K.C.; Yew, W.W.; Chan, R.C.Y. Rapid assays for fluoroquinolone resistance in Mycobacterium tuberculosis: A systematic review and meta-analysis. J. Antimicrob. Chemother., 2010, 65(8), 1551-1561.
[http://dx.doi.org/10.1093/jac/dkq202] [PMID: 20542907]

Ginsburg, A.S.; Grosset, J.H.; Bishai, W.R. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect. Dis., 2003, 3(7), 432-442.
[http://dx.doi.org/10.1016/S1473-3099(03)00671-6] [PMID: 12837348]

Matrat, S.; Veziris, N.; Mayer, C.; Jarlier, V.; Truffot-Pernot, C.; Camuset, J.; Bouvet, E.; Cambau, E.; Aubry, A. Functional analysis of DNA gyrase mutant enzymes carrying mutations at position 88 in the A subunit found in clinical strains of Mycobacterium tuberculosis resistant to fluoroquinolones. Antimicrob. Agents Chemother., 2006, 50(12), 4170-4173.
[http://dx.doi.org/10.1128/AAC.00944-06] [PMID: 17015625]

Cheng, A.F.B.; Yew, W.W.; Chan, E.W.C.; Chin, M.L.; Hui, M.M.M.; Chan, R.C.Y. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob. Agents Chemother., 2004, 48(2), 596-601.
[http://dx.doi.org/10.1128/AAC.48.2.596-601.2004] [PMID: 14742214]

Lau, R.W.T.; Ho, P.L.; Kao, R.Y.T.; Yew, W.W.; Lau, T.C.K.; Cheng, V.C.C.; Yuen, K.Y.; Tsui, S.K.W.; Chen, X.; Yam, W.C. Molecular characterization of fluoroquinolone resistance in Mycobacterium tuberculosis: Functional analysis of gyrA mutation at position 74. Antimicrob. Agents Chemother., 2011, 55(2), 608-614.
[http://dx.doi.org/10.1128/AAC.00920-10] [PMID: 20956608]

Li, Q.; Jiao, W.; Yin, Q.; Xu, F.; Li, J.; Sun, L.; Xiao, J.; Li, Y.; Mokrousov, I.; Huang, H.; Shen, A. Compensatory mutations of rifampin resistance are associated with transmission of multidrug-resistant Mycobacterium tuberculosis beijing genotype strains in China. Antimicrob. Agents Chemother., 2016, 60(5), 2807-2812.
[http://dx.doi.org/10.1128/AAC.02358-15] [PMID: 26902762]

de Vos, M.; Müller, B.; Borrell, S.; Black, P.A.; van Helden, P.D.; Warren, R.M.; Gagneux, S.; Victor, T.C. Putative compensatory mutations in the rpoC gene of rifampin-resistant Mycobacterium tuberculosis are associated with ongoing transmission. Antimicrob. Agents Chemother., 2013, 57(2), 827-832.
[http://dx.doi.org/10.1128/AAC.01541-12] [PMID: 23208709]

Swain, S.S.; Sharma, D.; Hussain, T.; Pati, S. Molecular mechanisms of underlying genetic factors and associated mutations for drug resistance in Mycobacterium tuberculosis. Emerg. Microbes Infect., 2020, 9(1), 1651-1663.
[http://dx.doi.org/10.1080/22221751.2020.1785334] [PMID: 32573374]

Ramaswamy, S.V.; Reich, R.; Dou, S.J.; Jasperse, L.; Pan, X.; Wanger, A.; Quitugua, T.; Graviss, E.A. Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2003, 47(4), 1241-1250.
[http://dx.doi.org/10.1128/AAC.47.4.1241-1250.2003] [PMID: 12654653]

Carter, A.P.; Clemons, W.M.; Brodersen, D.E.; Morgan-Warren, R.J.; Wimberly, B.T.; Ramakrishnan, V. Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature, 2000, 407(6802), 340-348.
[http://dx.doi.org/10.1038/35030019] [PMID: 11014183]

Banerjee, R.; Schecter, G.F.; Flood, J.; Porco, T.C. Extensively drug-resistant tuberculosis: New strains, new challenges. Expert Rev. Anti Infect. Ther., 2008, 6(5), 713-724.
[http://dx.doi.org/10.1586/14787210.6.5.713] [PMID: 18847407]

Okamoto, S.; Tamaru, A.; Nakajima, C.; Nishimura, K.; Tanaka, Y.; Tokuyama, S.; Suzuki, Y.; Ochi, K. Loss of a conserved 7‐methylguanosine modification in 16S rRNA confers low‐level streptomycin resistance in bacteria. Mol. Microbiol., 2007, 63(4), 1096-1106.
[http://dx.doi.org/10.1111/j.1365-2958.2006.05585.x] [PMID: 17238915]

Spies, F.S.; Almeida da Silva, P.E.; Ribeiro, M.O.; Rossetti, M.L.; Zaha, A. Identification of mutations related to streptomycin resistance in clinical isolates of Mycobacterium tuberculosis and possible involvement of efflux mechanism. Antimicrob. Agents Chemother., 2008, 52(8), 2947-2949.
[http://dx.doi.org/10.1128/AAC.01570-07] [PMID: 18541729]

Kambli, P.; Ajbani, K.; Nikam, C.; Sadani, M.; Shetty, A.; Udwadia, Z.; Georghiou, S.B.; Rodwell, T.C.; Catanzaro, A.; Rodrigues, C. Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables. Int. J. Mycobacteriol., 2016, 5(1), 1-6.
[http://dx.doi.org/10.1016/j.ijmyco.2015.09.001] [PMID: 26927983]

Reeves, A.Z.; Campbell, P.J.; Willby, M.J.; Posey, J.E. Disparities in capreomycin resistance levels associated with the rrs A1401G mutation in clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2015, 59(1), 444-449.
[http://dx.doi.org/10.1128/AAC.04438-14] [PMID: 25385119]

Jugheli, L.; Bzekalava, N.; de Rijk, P.; Fissette, K.; Portaels, F.; Rigouts, L. High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene. Antimicrob. Agents Chemother., 2009, 53(12), 5064-5068.
[http://dx.doi.org/10.1128/AAC.00851-09] [PMID: 19752274]

Maus, C.E.; Plikaytis, B.B.; Shinnick, T.M. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2005, 49(8), 3192-3197.
[http://dx.doi.org/10.1128/AAC.49.8.3192-3197.2005] [PMID: 16048924]

Zaunbrecher, M.A.; Sikes, R.D., Jr; Metchock, B.; Shinnick, T.M.; Posey, J.E. Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA, 2009, 106(47), 20004-20009.
[http://dx.doi.org/10.1073/pnas.0907925106] [PMID: 19906990]

Johansen, S.K.; Maus, C.E.; Plikaytis, B.B.; Douthwaite, S. Capreomycin binds across the ribosomal subunit interface using tlyA-encoded 2′-O-methylations in 16S and 23S rRNAs. Mol. Cell, 2006, 23(2), 173-182.
[http://dx.doi.org/10.1016/j.molcel.2006.05.044] [PMID: 16857584]

Stanley, R.E.; Blaha, G.; Grodzicki, R.L.; Strickler, M.D.; Steitz, T.A. The structures of the anti-tuberculosis antibiotics viomycin and capreomycin bound to the 70S ribosome. Nat. Struct. Mol. Biol., 2010, 17(3), 289-293.
[http://dx.doi.org/10.1038/nsmb.1755] [PMID: 20154709]

Migliori, G.B.; Lange, C.; Centis, R.; Sotgiu, G.; Mütterlein, R.; Hoffmann, H.; Kliiman, K.; De Iaco, G.; Lauria, F.N.; Richardson, M.D.; Spanevello, A.; Cirillo, D.M. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur. Respir. J., 2008, 31(6), 1155-1159.
[http://dx.doi.org/10.1183/09031936.00028708] [PMID: 18515555]

Via, L.E.; Cho, S.N.; Hwang, S.; Bang, H.; Park, S.K.; Kang, H.S.; Jeon, D.; Min, S.Y.; Oh, T.; Kim, Y.; Kim, Y.M.; Rajan, V.; Wong, S.Y.; Shamputa, I.C.; Carroll, M.; Goldfeder, L.; Lee, S.A.; Holland, S.M.; Eum, S.; Lee, H.; Barry, C.E., III Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean Patients with drug-resistant tuberculosis. J. Clin. Microbiol., 2010, 48(2), 402-411.
[http://dx.doi.org/10.1128/JCM.01476-09] [PMID: 20032248]

Malinga, L.; Brand, J.; Olorunju, S.; Stoltz, A.; van der Walt, M. Molecular analysis of genetic mutations among cross-resistant second-line injectable drugs reveals a new resistant mutation in Mycobacterium tuberculosis. Diagn. Microbiol. Infect. Dis., 2016, 85(4), 433-437.
[http://dx.doi.org/10.1016/j.diagmicrobio.2016.05.010] [PMID: 27298046]

Wilson, D.N. Ribosome-targeting antibiotics and mechanisms of bacterial resistance. Nat. Rev. Microbiol., 2014, 12(1), 35-48.
[http://dx.doi.org/10.1038/nrmicro3155] [PMID: 24336183]

Jnawali, H.N.; Yoo, H.; Ryoo, S.; Lee, K.J.; Kim, B.J.; Koh, W.J.; Kim, C.K.; Kim, H.J.; Park, Y.K. Molecular genetics of Mycobacterium tuberculosis resistant to aminoglycosides and cyclic peptide capreomycin antibiotics in Korea. World J. Microbiol. Biotechnol., 2013, 29(6), 975-982.
[http://dx.doi.org/10.1007/s11274-013-1256-x] [PMID: 23329063]

Njire, M.; Tan, Y.; Mugweru, J.; Wang, C.; Guo, J.; Yew, W.; Tan, S.; Zhang, T. Pyrazinamide resistance in Mycobacterium tuberculosis: Review and update. Adv. Med. Sci., 2016, 61(1), 63-71.
[http://dx.doi.org/10.1016/j.advms.2015.09.007] [PMID: 26521205]

Zhang, Y.; Mitchison, D. The curious characteristics of pyrazinamide: A review. Int. J. Tuberc. Lung Dis., 2003, 7(1), 6-21.
[PMID: 12701830]

Scorpio, A.; Lindholm-Levy, P.; Heifets, L.; Gilman, R.; Siddiqi, S.; Cynamon, M.; Zhang, Y. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 1997, 41(3), 540-543.
[http://dx.doi.org/10.1128/AAC.41.3.540] [PMID: 9055989]

Louw, G.E.; Warren, R.M.; Donald, P.R.; Murray, M.B.; Bosman, M.; Van Helden, P.D.; Young, D.B.; Victor, T.C. Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. Int. J. Tuberc. Lung Dis., 2006, 10(7), 802-807.
[PMID: 16848344]

Cheng, S.J.; Thibert, L.; Sanchez, T.; Heifets, L.; Zhang, Y. pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: Spread of a monoresistant strain in Quebec, Canada. Antimicrob. Agents Chemother., 2000, 44(3), 528-532.
[http://dx.doi.org/10.1128/AAC.44.3.528-532.2000] [PMID: 10681313]

Fivian-Hughes, AS; Houghton, J; Davis, EO Mycobacterium tuberculosis thymidylate synthase gene thyX is essential and potentially bifunctional, while thyA deletion confers resistance to p-aminosalicylic acid. Microbiol-Sgm, 2012, 158, 1388.
[http://dx.doi.org/10.1099/mic.0.X00002-0]

Rengarajan, J.; Sassetti, C.M.; Naroditskaya, V.; Sloutsky, A.; Bloom, B.R.; Rubin, E.J. The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria. Mol. Microbiol., 2004, 53(1), 275-282.
[http://dx.doi.org/10.1111/j.1365-2958.2004.04120.x] [PMID: 15225321]

Leung, K.L.; Yip, C.W.; Yeung, Y.L.; Wong, K.L.; Chan, W.Y.; Chan, M.Y.; Kam, K.M. Usefulness of resistant gene markers for predicting treatment outcome on second-line anti-tuberculosis drugs. J. Appl. Microbiol., 2010, 109(6), 2087-2094.
[http://dx.doi.org/10.1111/j.1365-2672.2010.04840.x] [PMID: 20854453]

Pym, A.S.; Saint-Joanis, B.; Cole, S.T. Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infect. Immun., 2002, 70(9), 4955-4960.
[http://dx.doi.org/10.1128/IAI.70.9.4955-4960.2002] [PMID: 12183541]

Lee, A.S.G.; Teo, A.S.M.; Wong, S.Y. Novel mutations in ndh in isoniazid-resistant Mycobacterium tuberculosis isolates. Antimicrob. Agents Chemother., 2001, 45(7), 2157-2159.
[http://dx.doi.org/10.1128/AAC.45.7.2157-2159.2001] [PMID: 11408244]

Alland, D.; Steyn, A.J.; Weisbrod, T.; Aldrich, K.; Jacobs, W.R., Jr Characterization of the Mycobacterium tuberculosis iniBAC promoter, a promoter that responds to cell wall biosynthesis inhibition. J. Bacteriol., 2000, 182(7), 1802-1811.
[http://dx.doi.org/10.1128/JB.182.7.1802-1811.2000] [PMID: 10714983]

Unissa, A.N.; Subbian, S.; Hanna, L.E.; Selvakumar, N. Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis. Infect. Genet. Evol., 2016, 45, 474-492.
[http://dx.doi.org/10.1016/j.meegid.2016.09.004] [PMID: 27612406]

Starks, A.M.; Gumusboga, A.; Plikaytis, B.B.; Shinnick, T.M.; Posey, J.E. Mutations at embB codon 306 are an important molecular indicator of ethambutol resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2009, 53(3), 1061-1066.
[http://dx.doi.org/10.1128/AAC.01357-08] [PMID: 19104018]

Sreevatsan, S.; Stockbauer, K.E.; Pan, X.; Kreiswirth, B.N.; Moghazeh, S.L.; Jacobs, W.R., Jr; Telenti, A.; Musser, J.M. Ethambutol resistance in Mycobacterium tuberculosis: Critical role of embB mutations. Antimicrob. Agents Chemother., 1997, 41(8), 1677-1681.
[http://dx.doi.org/10.1128/AAC.41.8.1677] [PMID: 9257740]

Mokrousov, I.; Narvskaya, O.; Limeschenko, E.; Otten, T.; Vyshnevskiy, B. Detection of ethambutol-resistant Mycobacterium tuberculosis strains by multiplex allele-specific PCR assay targeting embB306 mutations. J. Clin. Microbiol., 2002, 40(5), 1617-1620.
[http://dx.doi.org/10.1128/JCM.40.5.1617-1620.2002] [PMID: 11980930]

Lee, H.Y.; Myoung, H.J.; Bang, H.E.; Bai, G.H.; Kim, S.J.; Kim, J.D.; Cho, S.N. Mutations in the embB locus among Korean clinical isolates of Mycobacterium tuberculosis resistant to ethambutol. Yonsei Med. J., 2002, 43(1), 59-64.
[http://dx.doi.org/10.3349/ymj.2002.43.1.59] [PMID: 11854934]

Falzon, D.; Jaramillo, E.; Schünemann, H.J.; Arentz, M.; Bauer, M.; Bayona, J.; Blanc, L.; Caminero, J.A.; Daley, C.L.; Duncombe, C.; Fitzpatrick, C.; Gebhard, A.; Getahun, H.; Henkens, M.; Holtz, T.H.; Keravec, J.; Keshavjee, S.; Khan, A.J.; Kulier, R.; Leimane, V.; Lienhardt, C.; Lu, C.; Mariandyshev, A.; Migliori, G.B.; Mirzayev, F.; Mitnick, C.D.; Nunn, P.; Nwagboniwe, G.; Oxlade, O.; Palmero, D.; Pavlinac, P.; Quelapio, M.I.; Raviglione, M.C.; Rich, M.L.; Royce, S.; Rüsch-Gerdes, S.; Salakaia, A.; Sarin, R.; Sculier, D.; Varaine, F.; Vitoria, M.; Walson, J.L.; Wares, F.; Weyer, K.; White, R.A.; Zignol, M. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur. Respir. J., 2011, 38(3), 516-528.
[http://dx.doi.org/10.1183/09031936.00073611] [PMID: 21828024]

Caminero, J.A. Treatment of multidrug-resistant tuberculosis: Evidence and controversies. Int. J. Tuberc. Lung Dis., 2006, 10(8), 829-837.
[PMID: 16898365]

Nakatani, Y; Opel-Reading, HK; Merker, M Role of alanine racemase mutations in Mycobacterium tuberculosis d-cycloserine resistance. Antimicrob Agents Chemother., 2017, 61(12), e01575-e01517.
[http://dx.doi.org/10.1128/AAC.01575-17]

Chen, JM; Uplekar, S; Gordon, SV A point mutation in cycA partially contributes to the D-cycloserine resistance trait of mycobacterium bovis BCG vaccine strains. Plos One, 2012, 7(8), e43467.
[http://dx.doi.org/10.1371/journal.pone.0043467]

Chen, J.; Zhang, S.; Cui, P.; Shi, W.; Zhang, W.; Zhang, Y. Identification of novel mutations associated with cycloserine resistance in Mycobacterium tuberculosis. J. Antimicrob. Chemother., 2017, 72(12), 3272-3276.
[http://dx.doi.org/10.1093/jac/dkx316] [PMID: 28961957]

Vadwai, V.; Ajbani, K.; Jose, M.; Vineeth, V.P.; Nikam, C.; Deshmukh, M.; Shetty, A.; Soman, R.; Rodrigues, C. Can inhA mutation predict ethionamide resistance? Int. J. Tuberc. Lung Dis., 2013, 17(1), 129-130.
[http://dx.doi.org/10.5588/ijtld.12.0511] [PMID: 23146620]

Brossier, F.; Veziris, N.; Truffot-Pernot, C.; Jarlier, V.; Sougakoff, W. Molecular investigation of resistance to the antituberculous drug ethionamide in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2011, 55(1), 355-360.
[http://dx.doi.org/10.1128/AAC.01030-10] [PMID: 20974869]

Lakshmi, R.; Kumar, V.; Baskaran, M.; Sundar, S.; Rahman, F.; Selvakumar, N.; Ramachandran, R. Pattern of ethionamide susceptibility and its association with isoniazid resistance among previously treated tuberculosis patients from India. Braz. J. Infect. Dis., 2011, 15(6), 619-620.
[http://dx.doi.org/10.1016/S1413-8670(11)70264-1] [PMID: 22218528]

Boonaiam, S.; Chaiprasert, A.; Prammananan, T.; Leechawengwongs, M. Genotypic analysis of genes associated with isoniazid and ethionamide resistance in MDR-TB isolates from Thailand. Clin. Microbiol. Infect., 2010, 16(4), 396-399.
[http://dx.doi.org/10.1111/j.1469-0691.2009.02838.x] [PMID: 19486070]

Abe, C.; Kobayashi, I.; Mitarai, S.; Wada, M.; Kawabe, Y.; Takashima, T.; Suzuki, K.; Sng, L.H.; Wang, S.; Htay, H.H.; Ogata, H. Biological and molecular characteristics of Mycobacterium tuberculosis clinical isolates with low-level resistance to isoniazid in Japan. J. Clin. Microbiol., 2008, 46(7), 2263-2268.
[http://dx.doi.org/10.1128/JCM.00561-08] [PMID: 18508939]

Guo, H.; Seet, Q.; Denkin, S.; Parsons, L.; Zhang, Y. Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA. J. Med. Microbiol., 2006, 55(11), 1527-1531.
[http://dx.doi.org/10.1099/jmm.0.46718-0] [PMID: 17030912]

Vilchèze, C.; Av-Gay, Y.; Attarian, R.; Liu, Z.; Hazbón, M.H.; Colangeli, R.; Chen, B.; Liu, W.; Alland, D.; Sacchettini, J.C.; Jacobs, W.R., Jr Mycothiol biosynthesis is essential for ethionamide susceptibility in Mycobacterium tuberculosis. Mol. Microbiol., 2008, 69(5), 1316-1329.
[http://dx.doi.org/10.1111/j.1365-2958.2008.06365.x] [PMID: 18651841]

Kadura, S.; King, N.; Nakhoul, M.; Zhu, H.; Theron, G.; Köser, C.U.; Farhat, M. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid. J. Antimicrob. Chemother., 2020, 75(8), 2031-2043.
[http://dx.doi.org/10.1093/jac/dkaa136] [PMID: 32361756]